MedTrace Logo

Effectiveness of the HeartHab Application on Exercise Capacity in Patients With Coronary Artery Disease

NCT03102671 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-02-27

No results posted yet for this study

Summary

The recurrence of major cardiac events after infarction is very high, in some populations up to 20% in the first year. Optimal secondary prevention as organized in cardiac rehabilitation centers is effective in reducing both morbidity and mortality. However, many studies have shown that the participation and adherence rate in CR-programs is low in most European countries. Therefore, novel ways of delivering secondary prevention using information technology and self-monitoring are being explored. Hence, this study will investigate the effectiveness of a mobile, patient tailored, app based multidisciplinary telerehabilitation program (HeartHab app) in improving exercise capacity, lifestyle and risk factors in patients with coronary artery disease in a post-rehabilitation setting.

Conditions

Interventions

OTHER

Use of HeartHab application followed by usual care

use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)

OTHER

Usual care followed by the use of HeartHab application

Usual care (2 months) followed by the use of HeartHab application (two months)

Sponsors & Collaborators

  • Jessa Hospital

    collaborator OTHER

  • Hasselt University

    lead OTHER

Principal Investigators

  • Paul Dendale, prof. dr. · Hasselt University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-01-01
Completion
2018-01-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03102671 on ClinicalTrials.gov